Advertisement

MMW - Fortschritte der Medizin

, Volume 160, Issue 21–22, pp 52–61 | Cite as

Wen wann womit impfen?

Risikoimpfungen im Alter

  • Christina ForstnerEmail author
  • Anja Kwetkat
  • Benjamin Schleenvoigt
  • Mathias W. Pletz
FORTBILDUNG . ÜBERSICHT
  • 292 Downloads

Zusammenfassung

Im Alter wird der Mensch anfälliger für Infektionen, weshalb ein Impfschutz immer wichtiger wird. Allerdings ist die Impfantwort bei alten Menschen oft reduziert. Wie man dieser Tatsache begegnen kann und welche Impfungen sinnvoll sind, erfahren Sie hier.

Vaccinations in the elderly — who, when and which vaccine to use

Keywords

Polysaccharide vaccine conjugate vaccine influenza herpes zoster tetanus pertussis 

Literatur

  1. 1.
    Pletz MW, von Baum H, van der Linden M, Rohde G, Schutte H, Suttorp N, Welte T. The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. Pneumologie. 2012;66:470–5CrossRefGoogle Scholar
  2. 2.
    Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4:e004833CrossRefGoogle Scholar
  3. 3.
    Pletz MW, Ewig S, Lange C, Welte T, Hoffken G. Update Pneumonia 2012. Deut Med Wochenschr. 2012;137:2265–80CrossRefGoogle Scholar
  4. 4.
    Kwetkat A, Leischker A, Heppner HJ. Influenza: special aspects in old age. Zeitschrift fur Gerontologie und Geriatrie. 2018;51:585–93CrossRefGoogle Scholar
  5. 5.
    Poethko-Muller C, Schmitz R. [Vaccination coverage in German adults: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013;56:845–57CrossRefGoogle Scholar
  6. 6.
    Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. New Engl J Med. 2007;357:1373–81CrossRefGoogle Scholar
  7. 7.
    Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25CrossRefGoogle Scholar
  8. 8.
    von Baum H, Schweiger B, Welte T, Marre R, Suttorp N, Pletz MWR, Ewig S, Grp CS. How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia. Eur Respir. J 2011;37:1151–7CrossRefGoogle Scholar
  9. 9.
    Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008;32:199–206CrossRefGoogle Scholar
  10. 10.
    Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One 2017;12:e0169368.CrossRefGoogle Scholar
  11. 11.
    Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk—A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0146338.CrossRefGoogle Scholar
  12. 12.
    Pletz MW, Ewig S, Heppner HJ, Welte T. Position Paper on Adult Pneumococcal Vaccination: Position Paper of the German Respiratory Society and the German Geriatric Society. Pneumologie. 2015;69:633–7CrossRefGoogle Scholar
  13. 13.
    STIKO. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut 2017/2018. Epid Bull. 2017;34Google Scholar
  14. 14.
    Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep;2018:67:1–20CrossRefGoogle Scholar
  15. 15.
    Bericht zur Epidemiologie der Influenza in Deutschland Saison 2016/17. Influenza RKIA. 2017:1–122Google Scholar
  16. 16.
    Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases. 2012;12:36–44CrossRefGoogle Scholar
  17. 17.
    Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis. 2014;14:1228–39CrossRefGoogle Scholar
  18. 18.
    Casado I, Dominguez A, Toledo D, Chamorro J, Astray J, Egurrola M, Fernandez-Sierra MA, Martin V, Morales-Suarez-Varela M, Godoy P, Castilla J, Project PIWG. Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study. CMAJ 2018;190:E3–E12CrossRefGoogle Scholar
  19. 19.
    Sellers SA, Hagan RS, Hayden FG, Fischer WA, 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11:372–93CrossRefGoogle Scholar
  20. 20.
    Kwong JC, Schwartz KL, Campitelli MA. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378:2540–41CrossRefGoogle Scholar
  21. 21.
    Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scorland. Eur Respir J. 2018;51:1701794CrossRefGoogle Scholar
  22. 22.
    MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016:102:1953–56CrossRefGoogle Scholar
  23. 23.
    Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002;105:2143–7CrossRefGoogle Scholar
  24. 24.
    Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J. 2004;31:28–32PubMedPubMedCentralGoogle Scholar
  25. 25.
    STIKO. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Wissenschaftliche Begründung für die Empfehlung des quadrivalenten saisonalen Impfstoffs. Epid Bull. 2018;2:19–31Google Scholar
  26. 26.
    DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45CrossRefGoogle Scholar
  27. 27.
    Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, Cox MMJ, Team PSCS. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. N Engl J Med. 2017;376:2427–36CrossRefGoogle Scholar
  28. 28.
    Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2017;35:513–20CrossRefGoogle Scholar
  29. 29.
    Jacoby E, Jarrahian C, Hull HF, Zehrung D. Opportunities and challenges in delivering influenza vaccine by microneedle patch. Vaccine 2015;33:4699–704CrossRefGoogle Scholar
  30. 30.
    De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville Fradet M, Rochette L, Halperin SA. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182:174–9CrossRefGoogle Scholar
  31. 31.
    Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix((R))): results of two randomized trials. Vaccine. 2012;30:1721–8CrossRefGoogle Scholar
  32. 32.
    STIKO. Mitteilung der Ständigen Impfkommission beim Robert Koch-Institut (RKI) Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut - 2018/2019. Epid Bull. 2018;34Google Scholar
  33. 33.
    Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369:255–63CrossRefGoogle Scholar
  34. 34.
    Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170CrossRefGoogle Scholar
  35. 35.
    STIKO. Wissenschaftliche Begründung für die Entscheidung, die Herpes-zoster-Lebendimpfung nicht als Standardimpfung zu empfehlen. Epid Bull. 2017;36:391–411Google Scholar
  36. 36.
    Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911CrossRefGoogle Scholar
  37. 37.
    Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ, 2013;14:1015–26CrossRefGoogle Scholar
  38. 38.
    Schmader KE, Levin MJ, Gnann JW, Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922–8CrossRefGoogle Scholar
  39. 39.
    Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Jr., Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study G. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;52:2271–84CrossRefGoogle Scholar
  40. 40.
    Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P, Shingles Prevention Study G. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320–8CrossRefGoogle Scholar
  41. 41.
    Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN, Shingles Prevention Study G. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis, 2015;60:900–9CrossRefGoogle Scholar
  42. 42.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, Group ZOES. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96CrossRefGoogle Scholar
  43. 43.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC, Group ZOES. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016;375:1019–32CrossRefGoogle Scholar
  44. 44.
    Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell Q Rep. 2004;28:244–8PubMedGoogle Scholar
  45. 45.
    Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, de Gruijter M, van Dissel JT, Bredenbeek PJ, Visser LG. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011;6:e27753CrossRefGoogle Scholar
  46. 46.
    Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11:427–48CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Christina Forstner
    • 1
    • 2
    Email author
  • Anja Kwetkat
    • 3
  • Benjamin Schleenvoigt
    • 1
  • Mathias W. Pletz
    • 1
  1. 1.Institut für Infektionsmedizin und KrankenhaushygieneUniversitätsklinikum JenaJenaDeutschland
  2. 2.Universitätsklinik für Innere Medizin I, Klinische Abteilung für Infektionen und Tropenmedizin, Medizinische Universität WienWienÖsterreich
  3. 3.Klinik für GeriatrieUniversitätsklinikum JenaJenaDeutschland

Personalised recommendations